Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Otonomy Inc (OTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,167
  • Shares Outstanding, K 30,685
  • Annual Sales, $ 750 K
  • Annual Income, $ -50,370 K
  • 60-Month Beta 2.54
  • Price/Sales 104.21
  • Price/Cash Flow N/A
  • Price/Book 0.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.46
  • Number of Estimates 2
  • High Estimate -0.42
  • Low Estimate -0.50
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -24.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.43 +6.17%
on 04/18/19
3.02 -14.57%
on 03/20/19
-0.33 (-11.34%)
since 03/18/19
3-Month
1.90 +35.79%
on 01/23/19
3.02 -14.57%
on 03/20/19
+0.55 (+27.09%)
since 01/18/19
52-Week
1.50 +72.00%
on 12/27/18
4.85 -46.80%
on 05/18/18
-1.37 (-34.68%)
since 04/18/18

Most Recent Stories

More News
Report: Developing Opportunities within Noble, Harris, Jazz Pharmaceuticals, Teradata, Abeona Therapeutics, and Otonomy -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Noble Corporation (NYSE:NE),...

TDC : 44.99 (+1.28%)
JAZZ : 128.44 (+0.60%)
ABEO : 7.96 (-2.69%)
NE : 2.81 (unch)
HRS : 165.65 (-0.31%)
OTIC : 2.58 (+1.98%)
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313,...

OTIC : 2.58 (+1.98%)
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

ALPN : 7.59 (+4.40%)
OTIC : 2.58 (+1.98%)
MTEM : 6.28 (+2.87%)
TCDA : 31.16 (-1.11%)
ATNM : 0.31 (-31.55%)
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

KALV : 25.50 (+0.43%)
ACRX : 3.38 (+0.60%)
ALPN : 7.59 (+4.40%)
OTIC : 2.58 (+1.98%)
MTEM : 6.28 (+2.87%)
TCDA : 31.16 (-1.11%)
ATNM : 0.31 (-31.55%)
Will Otonomy Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Otonomy.

OTIC : 2.58 (+1.98%)
Otonomy to Participate in Two Upcoming Investor Conferences

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive...

OTIC : 2.58 (+1.98%)
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter...

OTIC : 2.58 (+1.98%)
Analysis: Positioning to Benefit within Apache, A. O. Smith, Diamondback Energy, Maiden, Lands' End, and Otonomy -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Apache Corporation (NYSE:APA),...

APA : 35.87 (-2.63%)
FANG : 107.28 (-0.89%)
AOS : 56.49 (+0.88%)
MHLD : 0.70 (-9.97%)
LE : 18.46 (+0.16%)
OTIC : 2.58 (+1.98%)
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for...

OTIC : 2.58 (+1.98%)
Otonomy Provides Corporate and Product Pipeline Update

Three programs with clinical trial results in 2020 including OTIVIDEX(TM) Phase 3 trial in Meniere's disease

OTIC : 2.58 (+1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade OTIC with:

Business Summary

Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle...

See More

Key Turning Points

2nd Resistance Point 2.72
1st Resistance Point 2.65
Last Price 2.58
1st Support Level 2.47
2nd Support Level 2.36

See More

52-Week High 4.85
Fibonacci 61.8% 3.57
Fibonacci 50% 3.17
Fibonacci 38.2% 2.78
Last Price 2.58
52-Week Low 1.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar